THOR - Synthorx, Inc.
| Previous Close | 16.62 |
| Open | 16.62 |
| Bid | 15.77 x 2900 |
| Ask | 16.04 x 800 |
| Day's Range | 15.77 - 16.81 |
| 52 Week Range | 11.00 - 23.53 |
| Volume | 40,244 |
| Avg. Volume | 142,030 |
| Market Cap | 499.472M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -18.11 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 28.75 |
- Motley Fool•2 days ago
3 Top Stocks That Aren't on Wall Street's Radar
Three companies in industries that Wall Street isn't paying enough attention to. Don't miss out, too.
- GlobeNewswire•23 days ago
Synthorx to Present at H.C. Wainwright Global Life Sciences Conference in London
Synthorx, Inc. (THOR), a biotechnology company using a first-of-its-kind Expanded Genetic Alphabet platform technology to discover and develop optimized biologics for cancer and autoimmune disorders, today announced that management will present at the H.C. Wainwright Global Life Sciences Conference held in London, UK. Synthorx, Inc. is a biotechnology company focused on prolonging and improving the lives of people with cancer and autoimmune disorders. Synthorx’s proprietary, first-of-its-kind Expanded Genetic Alphabet platform technology expands the genetic code by adding a new DNA base pair and is designed to create optimized biologics, referred to as Synthorins.
- GlobeNewswire•last month
Synthorx to Present at the American Association of Cancer Research (AACR) Annual Meeting 2019
Synthorx, Inc. (THOR), a biotechnology company using a first-of-its-kind Expanded Genetic Alphabet platform technology to discover and develop optimized biologics for cancer and autoimmune disorders, today announced the details of a poster presentation to be held at the American Association for Cancer Research (AACR) Annual Meeting 2019, taking place in Atlanta, Georgia. A Synthorin is a protein optimized through incorporation of novel amino acids encoded by the new DNA base pair that enables site-specific modifications, which enhance the pharmacological properties of these therapeutics.
- Associated Press•last month
Synthorx: 4Q Earnings Snapshot
On a per-share basis, the La Jolla, California-based company said it had a loss of $2.94. Losses, adjusted for non-recurring costs, were 89 cents per share. For the year, the company reported a loss of ...
- GlobeNewswire•last month
Synthorx Reports Fourth Quarter and Full Year 2018 Financial Results
Company Positioned for Upcoming 2019 Milestones After Successful IPO Raising $150.7 Million in Gross Proceeds Presented Preclinical Safety and Anti-Tumor Data on Lead Product.
- GlobeNewswire•last month
Synthorx to Present at the Chinese Society for Clinical Oncology Conference on Immunotherapy
Synthorx, Inc. (THOR), a biotechnology company using a first-of-its-kind Expanded Genetic Alphabet platform technology to discover and develop optimized biologics for cancer and autoimmune disorders, today announced the details of an oral presentation to be held at the Chinese Society for Clinical Oncology (CSCO) Conference on Immunotherapy, endorsed by the American Association for Cancer Research (AACR), taking place in Shanghai, China. The oral session will be held on March 22, 2019 from 15:30 China Standard Time.
- Benzinga•2 months ago
Small Cap Winners And Losers From Last Week
Although FANG’s 2019 troubles are making headlines and Kraft Heinz Co. (NASDAQ: KHC) just roiled the market with a truly stomach-turning fourth quarter earnings report, there’s a whole universe of small-cap stocks making waves of their own. Following a blowout fourth quarter earnings report delivered earlier in the month, Invacare Corporation (NYSE: IVC) has continued generating investor interest. More impressive is that the stock gained 13 percent on top of its initial spike in the days following its earnings announcement.
- GlobeNewswire•2 months ago
Synthorx to Present at the 8th Annual SVB Leerink Global Healthcare Conference
SAN DIEGO, Feb. 21, 2019 -- Synthorx, Inc. (NASDAQ: THOR), a biotechnology company using a first-of-its-kind Expanded Genetic Alphabet platform technology to discover and.
- GlobeNewswire•4 months ago
Synthorx Appoints Andrew Powell, J.D., to its Board of Directors
Synthorx, Inc. (THOR), a biotechnology company using a first-of-its-kind Expanded Genetic Alphabet platform technology to discover and develop optimized biologics for cancer and autoimmune disorders, today announced the appointment of Andrew Powell, J.D., to its board of directors. In addition, current board member Pratik Shah, Ph.D., has been appointed chairman of the board.
- GlobeNewswire•4 months ago
Synthorx Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Synthorx, Inc. (THOR), a biotechnology company using a first-of-its-kind Expanded Genetic Alphabet platform technology to discover and develop optimized biologics for cancer and autoimmune disorders, today announced the closing of its previously announced initial public offering of 13,699,636 shares of common stock, which includes the exercise in full of the underwriters’ option to purchase 1,786,909 additional shares of common stock, at a public offering price of $11.00 per share. Jefferies LLC, Leerink Partners LLC and Evercore ISI acted as joint book-running managers for the offering. H.C. Wainwright & Co., LLC acted as lead manager for the offering.
- GlobeNewswire•5 months ago
Synthorx Announces Pricing of Initial Public Offering
Synthorx, Inc. (THOR), a biotechnology company using a first-of-its-kind Expanded Genetic Alphabet platform technology to discover and develop optimized biologics for cancer and autoimmune disorders, today announced the pricing of its initial public offering of 11,912,727 shares of common stock at a public offering price of $11.00 per share. Synthorx anticipates total gross proceeds of approximately $131 million, before deducting underwriting discounts and commissions and other offering expenses. All shares of common stock are being offered by Synthorx. In addition, Synthorx has granted the underwriters a 30-day option to purchase up to an additional 1,786,909 shares of common stock at the initial public offering price.
- Yahoo Finance•5 months ago
Stocks pare losses, Nasdaq closes in the green
Stocks pared losses after enduring a rollercoaster session ignited after the arrest of a Chinese telecommunications company executive muddled prospects of a U.S.-China trade resolution.
- Benzinga•5 months ago
IPO Outlook For The Week: Proteins, Fashion And Finance
For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . Mogu Inc. (MOGU) will issue 4.75 million shares between $14 and $16 Wednesday on the New York Stock Exchange. The Chinese ...
